Literature DB >> 26930638

Optimal medical therapy may be a better initial strategy in patients with chronic total occlusion of a single coronary artery.

Ji-Won Hwang1, Jeong Hoon Yang2, Seung-Hyuk Choi3, Jin Kyung Hwang1, Woo Jin Jang1, Joo-Yong Hahn1, Young Bin Song1, Jin-Ho Choi1, Sang Hoon Lee1, Hyeon-Cheol Gwon1.   

Abstract

OBJECTIVES: To compare clinical outcomes of percutaneous coronary intervention (PCI) with those of optimal medical therapy (OMT) alone in patients with chronic total occlusion (CTO) of a single coronary artery.
BACKGROUND: Limited data are available on the efficacy of OMT for the treatment of single-vessel CTO.
METHODS: Between March 2003 and February 2012, we enrolled 2024 CTO patients in a retrospective, observational registry and analyzed 435 patients with CTO of a single coronary artery. We divided patients into an OMT group (n=147) and PCI group (n=288) according to the initial treatment strategy. One-to-many (1:N) propensity score matching with a non-fixed matching ratio was also performed. The primary outcome measured in this study was major adverse cardiac events (MACEs) including cardiac death, myocardial infarction, and repeated coronary revascularization.
RESULTS: The median follow-up duration was 47.6 (interquartile range: 22.9 to 68.9) months. Major adverse cardiac events were noted for 16 patients (10.9%) in the OMT group compared to 41 patients (14.2%) in the PCI group (p=0.38). After propensity-score matching, there were no significant differences between the OMT group and PCI group with respect to MACE frequency (10.1% vs. 16.9%, adjusted hazard ratio [HR], 2.03; 95% confidence interval [CI], 0.88-4.68, p=0.10) or cardiac death (OMT vs. PCI: 5.1% vs. 4.8%, HR, 1.14; 95% CI, 0.30-4.42, p=0.85). Subgroup analysis showed that the rate of MACEs was significantly lower in the OMT group compared to the PCI group among patients with an APPROACH score ≤ 18 and SYNTAX score ≤ 12.
CONCLUSIONS: As a treatment strategy in patients with single-vessel CTO, PCI did not reduce the risk of MACE or cardiac death. These results suggest that OMT may be a better initial strategy for patients as assessed by low APPROACH and SYNTAX scores.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chronic total occlusion; Optimal medical treatment; Revascularization

Mesh:

Substances:

Year:  2016        PMID: 26930638     DOI: 10.1016/j.ijcard.2016.02.084

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  What the surgeon needs to know about percutaneous coronary intervention treatment of chronic total occlusions.

Authors:  Satoru Mitomo; Ozan M Demir; Antonio Colombo; Sunao Nakamura; Alaide Chieffo
Journal:  Ann Cardiothorac Surg       Date:  2018-07

2.  Percutaneous Coronary Intervention Versus Medical Therapy for Chronic Total Occlusion of Coronary Arteries: A Systematic Review and Meta-Analysis.

Authors:  Ka Hou Christien Li; Ka Hei Gabriel Wong; Mengqi Gong; Tong Liu; Guangping Li; Yunlong Xia; Jeffery Ho; Luis Nombela-Franco; Abhishek C Sawant; Simon Eccleshall; Gary Tse; Vassilios S Vassiliou
Journal:  Curr Atheroscler Rep       Date:  2019-08-09       Impact factor: 5.113

Review 3.  Revascularization of chronic total occlusion coronary artery and cardiac regeneration.

Authors:  Ruoxi Liao; Zhihong Li; Qiancheng Wang; Hairuo Lin; Huijun Sun
Journal:  Front Cardiovasc Med       Date:  2022-08-25

4.  Percutaneous coronary intervention provided better long term results than optimal medical therapy alone in patients with chronic total occlusion: A meta-analysis.

Authors:  Dibbendhu Khanra; Vikas Mishra; Bhavna Jain; Shishir Soni; Yogesh Bahurupi; Bhanu Duggal; Sudhir Rathore; Santanu Guha; Sharad Agarwal; Puneet Aggarwal; SantoshKumar Sinha; Kumar Himanshu
Journal:  Indian Heart J       Date:  2020-07-24

5.  The success of opening concurrent chronic total occlusion lesion to improve cardiac function trial in patients with multi-vessel disease (SOS-moral): Study protocol of a prospective multicenter study.

Authors:  Jinfan Tian; Huijuan Zuo; Lijun Zhang; Mingduo Zhang; Dongfeng Zhang; Min Zhang; Yuan Zhou; Yi He; Hongzhi Mi; Xueyao Yang; Rongchong Huang; Xiantao Song
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.